IGF-1 DES

Quick answer: IGF-1 DES (des(1-3)IGF-1) is a truncated, 67-amino-acid variant of insulin-like growth factor 1 missing the first three N-terminal residues. That deletion sharply reduces its binding to IGF-binding proteins (IGFBPs), leaving more of the molecule free to act on the IGF-1 receptor and making it roughly 4 to 10 times more potent than intact IGF-1 in cell-culture assays. It also clears the body much faster than IGF-1, with a reported half-life of only about 20 to 30 minutes. It is not approved for any use, not sold by any licensed pharmacy, and has never been tested in a human clinical trial – every claim about its effects in people comes from animal research, cell studies, or unverified anecdote.

Research snapshot

Technical identity

What is IGF-1 DES?

Insulin-like growth factor 1 (IGF-1) is a hormone the body makes mostly in the liver, under the control of growth hormone, that drives cell growth and division throughout the body. In blood, almost all of it is bound up by a family of carrier proteins called IGF-binding proteins (IGFBPs), which control how much free IGF-1 is actually available to act on cells at any given moment. IGF-1 DES is a naturally occurring, shortened form of IGF-1, missing the first three amino acids off one end of the molecule. That small deletion happens to sit right where IGF-1 normally grabs onto its binding proteins, so the truncated form binds them far more weakly. With less of it locked up by IGFBPs, more of the molecule is free to reach IGF-1 receptors on cells – which is why, despite being a smaller, “less complete” version of IGF-1, it behaves as a substantially more potent growth signal in laboratory assays.

It was identified and characterized by researchers studying how IGF-1 is naturally processed and degraded in the body, not developed as a drug candidate from scratch. It has never advanced into human clinical testing and exists today mainly as a laboratory research tool and, separately, as an unregulated compound sold online for research use, popular in the bodybuilding and physique communities for a theory about localized muscle growth that has not been tested in humans.

How does it work?

Plain-English explanation

Picture IGF-1 as a growth signal that’s mostly kept in “locked” storage by carrier proteins in the blood, with only a small fraction free to act at any time. IGF-1 DES is missing the piece of the molecule those carrier proteins normally grab onto, so it slips past that storage system and stays “unlocked” and active. That’s the entire basis for its extra potency – it isn’t a stronger signal at the receptor itself, there’s just more of it around to deliver the signal. It also gets cleared out of the body very quickly, within around 20 to 30 minutes, compared to hours for regular IGF-1, which is why it’s discussed as a tool for a short, localized burst of activity right where it’s injected rather than a lasting, whole-body effect.

Technical explanation

The N-terminal tripeptide removed in des(1-3)IGF-1 includes Glu-3, a residue central to IGF-1’s interaction with IGFBPs. Its absence reduces IGFBP affinity dramatically while leaving affinity for the type 1 IGF receptor essentially intact, which is why the potency advantage over intact IGF-1 (roughly 4- to 10-fold in cell-based assays, commonly cited around tenfold) disappears in IGFBP-free experimental systems – confirming the effect is a sequestration/bioavailability phenomenon, not an enhanced receptor interaction. Pharmacokinetically, des(1-3)IGF-1 is cleared much faster than intact IGF-1; in rats, metabolic clearance was measured at 4.59 mL/min/kg versus 1.20 mL/min/kg for IGF-1, with rapid tissue uptake, consistent with its short reported half-life and the “localized burst” framing used in community discussion.

Potential benefits and research applications

Localized skeletal muscle growth signaling

This is the theory driving essentially all of the compound’s use in the bodybuilding/RUO community: because it acts quickly and clears fast, injecting it directly into a specific muscle is proposed to trigger localized hypertrophy signaling in that muscle without materially raising systemic IGF-1 exposure elsewhere. This is a mechanistic hypothesis built on the pharmacokinetic profile described above; it has not been demonstrated in a controlled human or animal trial specifically testing localized intramuscular injection for hypertrophy outcomes.

Growth-hormone-axis and IGFBP research

Academically, des(1-3)IGF-1 has mainly been used as a research tool to study how IGFBPs regulate IGF-1 activity, since comparing intact IGF-1 to the truncated, IGFBP-resistant form lets researchers isolate the binding-protein’s contribution from the hormone’s intrinsic receptor activity. This has been shown in cell culture and animal models across several species (rat, pig, marmoset) from studies conducted mainly in the late 1980s through the 1990s; it has not translated into any approved clinical application.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Explanation of the reported figures

None of the mcg dosing figures above come from a published study of any kind – there is no human dosing research to trace them to. They are entirely community-generated, built by extrapolation from general RUO peptide-dosing conventions and from bodybuilding-forum trial and error, not from any pharmacokinetic or efficacy study in humans or animals testing these specific amounts. The near-universal advice to inject locally, near the target muscle, and only on training days, follows directly from the pharmacokinetic data that is real (a roughly 20–30 minute half-life and rapid tissue clearance) even though the specific mcg amounts and the growth outcome they’re meant to produce have not been tested. The consistent post-workout, with-carbohydrate timing advice traces to IGF-1’s well-documented insulin-like hypoglycemic effect, which is a real, mechanistically grounded safety concern, not dosing folklore.

Detailed dosage and protocol evidence

Amounts studied in human research

No established or reliably sourced human dosing information was identified. No published human trial of any kind was located.

Amounts studied in animal research

Practitioner and community-reported protocols

Conflicts and unanswered questions

There is no human data at any dose, so every mcg figure circulating online is unverified. The core pharmacokinetic claims (potency multiplier, half-life) are reasonably consistent across sources and trace back to the same handful of older primary studies, but the specific human injection protocols built on top of that pharmacology are not independently supported. Whether local intramuscular injection actually produces meaningfully localized rather than systemic effects in a living person has not been directly tested.

Important published research

Ballard et al. 1996, International Journal of Biochemistry & Cell Biology

A review consolidating the characterization of des(1-3)IGF-1 as a truncated form of IGF-1, covering its reduced IGFBP binding, its increased potency in cell and animal assays relative to intact IGF-1, and its more rapid clearance. This is preclinical review-level evidence, not a single controlled trial, and it does not include any human data.

Timing, duration, and research variables

The compound’s short reported half-life (roughly 20–30 minutes) and rapid tissue clearance are the basis for essentially all timing advice in circulation: inject shortly before or after training, near the target muscle, with carbohydrate available around the same time because of its insulin-like hypoglycemic potential. None of this specific timing protocol has been tested in a controlled study; it is inference drawn from real pharmacokinetic data plus general knowledge of IGF-1’s glucose-lowering effect.

Combinations and related research

Formally studied combinations: none identified in a controlled human or animal efficacy trial.

Practitioner and community-reported combinations: pairing with growth-hormone secretagogues (CJC-1295, Ipamorelin) for a combined systemic-plus-local growth strategy, with BPC-157 and TB-500 for injury/tendon repair protocols, and with MK-677 for longer-term IGF-1 elevation alongside site-specific dosing. None of these combinations has been tested in a controlled trial; they are community practice built on the individual compounds’ separate, mostly preclinical, evidence bases.

Side effects, risks, and limitations

• Hypoglycemia is a real, mechanism-based risk: IGF-1 and its analogs have insulin-like activity, and this risk is described in community sources as dose-dependent and worse with higher doses or fasted-state injection.
• Local injection-site irritation and transient water retention are commonly reported, without controlled data behind the frequency or severity.
• No controlled human safety data exist at any dose or duration.
• As an unregulated research chemical, purity, dose accuracy, and correct compound identity cannot be assumed from any vial purchased online.
• Any growth-factor compound carries a theoretical concern about unwanted proliferative signaling with chronic, high-dose, off-label use; this has not been specifically studied for des(1-3)IGF-1 in humans.

Regulatory and developmental status

IGF-1 DES is not approved for any human use in any country and holds no marketing authorization anywhere. It is not in active pharmaceutical development as a drug candidate; it functions today as a laboratory research reagent and, separately, as an unregulated compound sold online for research use only, with no clinical development pathway underway.

Frequently asked questions

What is IGF-1 DES?

A shortened, 67-amino-acid version of insulin-like growth factor 1, missing its first three residues, which makes it bind carrier proteins in the blood much more weakly and act as a more potent, faster-acting, faster-clearing growth signal than intact IGF-1.

How does it work?

By evading IGF-binding proteins that normally keep most circulating IGF-1 inactive, leaving more of the molecule free to activate IGF-1 receptors, and by clearing the body quickly, which is why it’s discussed as producing a short, localized burst of activity rather than a sustained systemic one.

What dosage has been studied?

No established or reliably sourced dosing information was identified for any species, human or animal, at the level of a specific formal dosing study designed to establish an effective human amount. No human dosing study exists at all.

What dosage commonly circulates online?

20 to 100 mcg per local injection, typically titrated upward from 20 mcg, on training days only, roughly four times a week, in 4-6 week cycles. This range is entirely community-generated and has no study behind it.

How frequently is it reported?

Community protocols describe dosing only on training days, about four times per week, rather than daily.

What routes are reported?

Local subcutaneous or intramuscular injection near the target muscle. It is not orally active.

How long do reported protocols last?

Commonly 4 to 6 weeks on, followed by 2 to 4 weeks off, per community sources; injury-repair protocols are sometimes reported as shorter, 2 to 4 weeks. None of this is derived from a study.

Has it been studied in humans?

No. No published human clinical trial of any kind was identified for this compound. All available evidence is animal or cell-culture research, most of it from the late 1980s through the 1990s.

What side effects have been reported?

Hypoglycemia is the main mechanism-based concern, given IGF-1’s insulin-like activity, along with commonly reported local injection-site irritation. None of this comes from controlled human data.

Is it approved?

No. It is not approved for any human use anywhere and is not in active pharmaceutical development. It exists only as a research reagent and as an unregulated research-use-only product sold online.

What remains unknown?

Essentially everything about its effects in humans: there is no human efficacy data, no human safety data, and no study of whether local injection actually produces a meaningfully localized rather than systemic effect. All the specific mcg dosing protocols in circulation are unverified community practice, not research findings.

Bottom line

IGF-1 DES is a real, well-characterized molecule with a genuinely interesting mechanism – a small N-terminal deletion that lets it evade the body’s normal IGF-1 storage system, making it several times more potent and much faster-clearing than intact IGF-1 in laboratory settings. That much is solid preclinical science from research going back to the late 1980s and 1990s. What is not solid is everything downstream of it: there is no human clinical trial of any kind, no established human dosage, and no direct evidence that local injection near a specific muscle produces the targeted growth effect the theory predicts, rather than diffusing into general circulation like other injected peptides. Every mcg figure, every cycle length, and every stacking protocol found online for this compound is community-generated, built from general RUO dosing conventions and the underlying (real) pharmacokinetic data, not from any study that actually tested those amounts in a living organism. It is not approved anywhere, not in active drug development, and anything purchased online carries the same identity and purity uncertainty as any other unregulated research chemical.

Sources

• Ballard FJ, et al. “Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I.” International Journal of Biochemistry & Cell Biology, 1996. PMID 8930132. Published preclinical review.
• Wikipedia. “Des(1-3)IGF-1.” Compilation of chemical identity, potency, and pharmacokinetic data with citations to primary literature. Educational source.
• ChemicalBook. IGF-1 DES chemical identifier listing (CAS 112603-35-7, molecular formula, molecular weight). Commercial/chemical-database listing, cited for identifiers only.
• Condor Research, Swolverine, and PeptideDosage.org. Community and vendor-adjacent research-use-only education pages. Cited for circulating dosage and stacking claims only, not as evidence of safety or efficacy.